Evidence map›Paper›PMID 37337413›Full record

ArticleCancer science2023

Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma.

Yu Igata, Motohiro Kojima, Toshiyuki Suzuki, Genichiro Ishii, Ryo Morisue, Toshihiro Suzuki, Masashi Kudo, Motokazu Sugimoto, Shin Kobayashi, John D Martin and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

Yu IgataDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0001-5074-417X
Motohiro KojimaDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-6150-6545
Toshiyuki SuzukiDepartment of Surgery, Hanyu General Hospital, Hanyu, Japan.
Genichiro IshiiDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0001-8637-3323
Ryo MorisueDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Toshihiro SuzukiDivision of Pharmacology, School of Medicine, Teikyo University, Tokyo, Japan.
Masashi KudoDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0003-2161-1807
Motokazu SugimotoDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Shin KobayashiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0001-9321-8452
John D MartinRed Arrow Therapeutics Co., Ltd, Tokyo, Japan.
Triantafyllos StylianopoulosCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus.
Horacio CabralDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Mitsunobu R KanoDepartment of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.
Masaru KonishiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Naoto GotohdaDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
National Cancer Center Hospital East · JPHanil General Hospital · KRJuntendo University · JPArrow International (United States) · USOkayama University · JPThe University of Tokyo · JPUniversity of Cyprus · CY

Funding

Fund for the Promotion of Joint International Research 21K
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is physically palpated as a hard tumor with an unfavorable prognosis. Assessing physical features and their association with pathological features could help to elucidate the mechanism of physical abnormalities in cancer tissues. A total of 93 patients who underwent radical surgery for pancreatic and bile duct cancers at a single center hospital during a 28-month period were recruited for this study that aimed to estimate the stiffness of PDAC tissues compared to the other neoplasms and assess relationships between tumor stiffness and pathological features. Physical alterations and pathological features of PDAC, with or without preoperative therapy, were analyzed. The immunological tumor microenvironment was evaluated using multiplexed fluorescent immunohistochemistry. The stiffness of PDAC correlated with the ratio of Azan-Mallory staining, α-smooth muscle actin, and collagen I-positive areas of the tumors. Densities of CD8

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsCD8-Positive T-LymphocytesHumansPrognosisTumor Microenvironmentelasticityimmunologypancreatic neoplasmpathologytumor microenvironment

Identifiers

PMID37337413
PMCPMC10475771
OpenAlexW4381308516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.